These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14632211)

  • 1. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application.
    Duvic M; Ni X; Talpur R; Herne K; Schulz C; Sui D; Ward S; Joseph A; Hazarika P
    J Invest Dermatol; 2003 Oct; 121(4):902-9. PubMed ID: 14632211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene.
    Orlandi A; Bianchi L; Costanzo A; Campione E; Giusto Spagnoli L; Chimenti S
    J Invest Dermatol; 2004 Apr; 122(4):1037-41. PubMed ID: 15102095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer.
    Duvic M; Helekar B; Schulz C; Cho M; DiSepio D; Hager C; DiMao D; Hazarika P; Jackson B; Breuer-McHam J; Young J; Clayman G; Lippman SM; Chandraratna RA; Robinson NA; Deucher A; Eckert RL; Nagpal S
    Clin Cancer Res; 2000 Aug; 6(8):3249-59. PubMed ID: 10955811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of topical tazarotene: a review.
    Talpur R; Cox K; Duvic M
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):195-210. PubMed ID: 20213916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases.
    Bianchi L; Orlandi A; Campione E; Angeloni C; Costanzo A; Spagnoli LG; Chimenti S
    Br J Dermatol; 2004 Jul; 151(1):148-56. PubMed ID: 15270884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma.
    Peris K; Ferrari A; Fargnoli MC; Piccolo D; Chimenti S
    Dermatol Surg; 2005 Feb; 31(2):217-20. PubMed ID: 15762218
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular mechanisms of tazarotene action in psoriasis.
    Duvic M; Nagpal S; Asano AT; Chandraratna RA
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S18-24. PubMed ID: 9270552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin.
    Nagpal S; Patel S; Jacobe H; DiSepio D; Ghosn C; Malhotra M; Teng M; Duvic M; Chandraratna RA
    J Invest Dermatol; 1997 Jul; 109(1):91-5. PubMed ID: 9204961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis.
    So PL; Fujimoto MA; Epstein EH
    Mol Cancer Ther; 2008 May; 7(5):1275-84. PubMed ID: 18483315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tazarotene in the treatment of psoriasis.
    Marks R
    Br J Dermatol; 1999 Apr; 140 Suppl 54():24-8. PubMed ID: 10731131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ.
    Bardazzi F; Bianchi F; Parente G; Guareschi E; Landi C
    J Am Acad Dermatol; 2005 Jun; 52(6):1102-4. PubMed ID: 15928641
    [No Abstract]   [Full Text] [Related]  

  • 12. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.
    Tang JY; Chiou AS; Mackay-Wiggan JM; Aszterbaum M; Chanana AM; Lee W; Lindgren JA; Raphael MA; Thompson BJ; Bickers DR; Epstein EH
    Cancer Prev Res (Phila); 2014 Mar; 7(3):292-9. PubMed ID: 24441673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
    Tang-Liu DD; Matsumoto RM; Usansky JI
    Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis].
    Wang QY; Yan HL; Liu P; Peng ZH; Tan SS
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1146-8. PubMed ID: 16939905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confluent and reticulated papillomatosis: response to tazarotene.
    Bowman PH; Davis LS
    J Am Acad Dermatol; 2003 May; 48(5 Suppl):S80-1. PubMed ID: 12734485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study.
    Apisarnthanarax N; Talpur R; Ward S; Ni X; Kim HW; Duvic M
    J Am Acad Dermatol; 2004 Apr; 50(4):600-7. PubMed ID: 15034511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keratin 4 upregulation by retinoic acid in vivo: a sensitive marker for retinoid bioactivity in human epidermis.
    Virtanen M; Törmä H; Vahlquist A
    J Invest Dermatol; 2000 Mar; 114(3):487-93. PubMed ID: 10692107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis.
    Nagpal S; Thacher SM; Patel S; Friant S; Malhotra M; Shafer J; Krasinski G; Asano AT; Teng M; Duvic M; Chandraratna RA
    Cell Growth Differ; 1996 Dec; 7(12):1783-91. PubMed ID: 8959347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
    Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
    Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis.
    Schiener R; Behrens-Williams SC; Pillekamp H; Kaskel P; Peter RU; Kerscher M
    Br J Dermatol; 2000 Dec; 143(6):1275-8. PubMed ID: 11122033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.